WO2012098501A1 - Co-cristaux de fébuxostat - Google Patents

Co-cristaux de fébuxostat Download PDF

Info

Publication number
WO2012098501A1
WO2012098501A1 PCT/IB2012/050230 IB2012050230W WO2012098501A1 WO 2012098501 A1 WO2012098501 A1 WO 2012098501A1 IB 2012050230 W IB2012050230 W IB 2012050230W WO 2012098501 A1 WO2012098501 A1 WO 2012098501A1
Authority
WO
WIPO (PCT)
Prior art keywords
febuxostat
crystal
crystals
caffeine
urea
Prior art date
Application number
PCT/IB2012/050230
Other languages
English (en)
Inventor
Poonam KAUSHIK
Ram Thaimattam
Mohan Prasad
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2012098501A1 publication Critical patent/WO2012098501A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Definitions

  • the present invention relates to co-crystals of febuxostat, processes for their preparation and their use for the chronic management of hyperuricemia in patients with gout.
  • Febuxostat is a non-purine xanthine oxidase inhibitor disclosed in U.S. Patent No. 5,614,520. It is chemically described as 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4- methylthiazole-5-carboxylic acid having the structure as represented by Formula I.
  • Febuxostat is marketed in the United States as a white crystalline powder under the brand name Uloric® for the chronic management of hyperuricemia in patients with gout.
  • Uloric® for the chronic management of hyperuricemia in patients with gout.
  • the present invention provides for a febuxostat-urea co- crystal with X-ray diffraction peaks having d-spacing values at about 1 1.73, 7.78, 5.87, 5.1 1 and 3.55 A.
  • Embodiments of this aspect of the invention may include one or more of the following features.
  • the febuxostat-urea co-crystal may further include X-ray diffraction peaks having d-spacing values at about 6.86, 4.96, 3.90, 3.68 and 3.16 A.
  • the febuxostat-urea co-crystal may also include a DSC having an endotherm at about 170°C.
  • the febuxostat and the urea may be in a 1 : 1 stoichiometric ratio.
  • the present invention provides for a'febuxostat- nicotinamide co-crystal with X-ray diffraction peaks having d-spacing values at about 17.14, 7.18, 5.68, 3.54 and 3.32 A.
  • Embodiments of this aspect of the invention may include one or more of the following features.
  • the febuxostat-nicotinamide co-crystal may further include X-ray diffraction peaks having d-spacing values at about 4.21, 3.87, 3.76, 3.50 and 3.19 A.
  • the febuxostat-nicotinamide co-crystal may also include a DSC having an endotherm at about 143.45°C.
  • the febuxostat and the nicotinamide may be in a 1 : 1 stoichiometric ratio.
  • the present invention provides for a febuxostat- caffeine co-crystal with X-ray diffraction peaks having d-spacing values at about 8.76, 7.63, 7.10, 3.40 and 3.36 A.
  • Embodiments of this aspect of the invention may include one or more of the following features.
  • the febuxostat-caffeine co-crystal may further include X- ray diffraction peaks having d-spacing values at about 5.15, 4.85, 4.30, 3.82, 3.48 and 3.27 A.
  • the febuxostat-caffeine co-crystal may also include a DSC having an endotherm at about 193.54°C.
  • the febuxostat and the caffeine may be in a 1 :2 stoichiometric ratio.
  • the present invention provides for a process for the preparation of co-crystals of febuxostat with a co-crystal forms selected from urea, nicotinamide or caffeine which includes contacting febuxostat of Formula I,
  • Embodiments of this aspect of the present invention may include one or more of the following features.
  • the febuxostat is contacted with the co-crystal former in a solvent selected from water, alcohols, ketones, carboxylic acids, chlorinated hydrocarbons, ethers, amides, sulphoxides, alkyl acetates, or mixtures thereof.
  • the febuxostat may be contacted with the co-crystal former in acetone.
  • the febuxostat may also be contacted with the co-crystal former in ethanol or the febuxostat may be contacted with the co-crystal former in 2-propanol.
  • the febuxostat may be contacted with the co-crystal former at ambient temperature to reflux temperature of solvent(s).
  • the reaction mixture containing febuxostat and the co-crystal former in solvent(s) may also be kept at a temperature of about -18°C to about -20°C.
  • the co-crystals of febuxostat may be purified by crystallization from a solvent selected from the group of alcohols, ketones, water, carboxylic acids, chlorinated hydrocarbons, amides, sulphoxides, ethers, or mixtures thereof.
  • the present invention provides for a pharmaceutical composition which includes co-crystals of febuxostat selected from febuxostat-urea, febuxostat-nicotinamide or febuxostat-caffeine and one or more pharmaceutically acceptable carriers, diluents or excipients.
  • the present invention provides for the use of co- crystals of febuxostat selected from febuxostat-urea, febuxostat-nicotinamide or febuxostat-caffeine for chronic management of hyperuricemia in patients with gout.
  • Figure 1 X-ray diffraction pattern (XRD) of febuxostat-urea co-crystal.
  • FIG. 1 Differential Scanning Thermogram (DSC) of febuxostat-urea co-crystal.
  • Figure 4 X-ray diffraction pattern of febuxostat-nicotinamide co-crystal.
  • Figure 5 Differential Scanning Thermogram of febuxostat-nicotinamide co- crystal.
  • Figure 7 X-ray diffraction pattern of febuxostat-caffeine co-crystal.
  • Figure 8 Differential Scanning Thermogram of febuxostat-caffeine co-crystal.
  • Figure 9 Thermogravimetric Analysis of febuxostat-caffeine co-crystal.
  • Figure 10 X-ray diffraction pattern overlay of febuxostat, urea, and febuxostat- urea co-crystal.
  • Figure 1 1 X-ray diffraction pattern overlay of febuxostat, nicotinamide, and
  • Figure 12 X-ray diffraction pattern overlay of febuxostat, caffeine, and febuxostat- caffeine co-crystal.
  • Figure 13 DSC overlay of febuxostat, urea, and febuxostat-urea co-crystal.
  • Figure 14 DSC overlay of febuxostat, nicotinamide, and febuxostat-nicotinamide co-crystal.
  • Figure 15 DSC overlay of febuxostat, caffeine, and febuxostat-caffeine co-crystal.
  • Febuxostat-urea co-crystals of the present invention may be characterized by XRD peaks at about 7.54 (d-spacing at about 1 1.73 A), 1 1.37 (7.78 A), 15.09 (5.87 A), 17.33 (5.1 1 A) and 25.10 (3.55 A) ⁇ 0.2° 2 ⁇ . It may be further characterized by XRD peaks at about 12.90 (6.86 A), 17.87 (4.96 A), 22.81 (3.90 A), 24.21 (3.68 A) and 28.23 (3.16 A) ⁇ 0.2° 2 ⁇ .
  • Febuxostat-urea co-crystal may also be characterized by DSC having endoderm at about 170°C.
  • Table 1 provides the d-spacing in A and the corresponding 2 ⁇ values of febuxostat-urea co-crystals.
  • Febuxostat-nicotinamide co-crystals of the present invention may be characterized by XRD peaks at about 5.16 (d-spacing at about 17.14A), 12.32 (7.18 A), 15.61 (5.68 A), 25.17 (3.54 A) and 26.87 (3.32 A) ⁇ 0.2° 2 ⁇ . It may be further characterized by XRD peaks at about 21.09 (4.21 A), 22.96 (3.87 A), 23.63 (3.76 A), 25.41 (3.50 A) and 27.96 (3.19 A) ⁇ 0.2° 2 ⁇ .
  • Febuxostat-nicotinamide co-crystal may also be characterized by DSC having endoderm at about 143.45°C.
  • Febuxostat-caffeine co-crystals of the present invention may be characterized by XRD peaks at about 10.10 (d-spacing at about 8.76 A), 1 1.59 (7.63 A), 12.47 (7.10 A), 26.24 (3.40 A) and 26.52 (3.36 A) ⁇ 0.2° 2 ⁇ . It may be further characterized by XRD peaks at about 17.21 (5.15 A), 18.28 (4.85 A), 20.65 (4.30 A), 23.28 (3.82 A), 25.57 (3.48 A) and 27.31 (3.27 A) ⁇ 0.2° 2 ⁇ .
  • Febuxostat-caffeine co-crystal may also be characterized by DSC having endotherm at about 193.54°C.
  • Febuxostat to be used for the preparation of febuxostat co-crystals of the present invention may be obtained by any of the methods known in the literature such as those described in U.S. Patent No. 5,614,520; U.S. Publication No. 2009/0203919; and U.S. Patent No.7,541 ,475, which are incorporated herein by reference.
  • Febuxostat to be used as starting material for the preparation of febuxostat co-crystals of the present invention may be obtained as a solution directly from a reaction in which it is formed and used as such without isolation.
  • contacting may include dissolving, slurrying, stirring or a combination thereof.
  • ambient temperature refers to a temperature in the range of about 20°C to about 30°C.
  • co-crystal refers to a crystalline material that includes two or more unique components held together by a weak interaction in a stoichiometric ratio, wherein at least one of the compounds is a co-crystal former, and wherein each component of the co-crystal has distinctive physical characteristics such as structure, melting point and heat of fusion.
  • weak interaction refers to an interaction which is neither ionic nor covalent and includes interactions such as hydrogen bonds, Vander Waals forces and ⁇ - ⁇ interactions.
  • co-crystal former refers to a compound capable of interacting with febuxostat through hydrogen bonding, Vander Waals forces or ⁇ - ⁇ interactions.
  • the co-crystal former may be selected from the compounds having at least one functional group selected from urea, amide or ketone.
  • co-crystal formers having urea functional group may include urea or 4-ethoxyphenyl urea.
  • co- crystal formers having amide group may include nicotinamide or iso-nicotinamide.
  • co-crystal forms having a ketone group may include caffeine.
  • the co-crystal formers of the present invention are acceptable food additives.
  • the febuxostat co-crystals of the present invention may have a specific
  • the co-crystal former is urea and the febuxostat-urea co-crystals are formed by the interaction of febuxostat and urea in 1 : 1 stoichiometric ratio.
  • the co-crystal former is nicotinamide and the febuxostat-nicotinamide co-crystals are formed by the interaction of febuxostat and nicotinamide in 1 : 1 stoichiometric ratio.
  • the co-crystal former is caffeine and the febuxostat- caffeine co-crystals are formed by the interaction of febuxostat and caffeine in 1 :2 stoichiometric ratio.
  • the preparation of febuxostat co-crystals may be carried out by contacting febuxostat with a co-crystal former in a solvent.
  • the solvent may be selected from the group of water, alcohols, ketones, carboxylic acids, chlorinated hydrocarbons, ethers, amides, sulphoxides, alkyl acetates or mixtures thereof.
  • Suitable alcohols may include methanol, ethanol, 1-propanol, 2-propanol, 1-butanol or 2-butanol.
  • Suitable ketones may include acetone, dimethyl ketone, ethyl methyl ketone or methyl iso-butyl ketone.
  • Suitable carboxylic acids may include formic acid, acetic acid or propionic acid.
  • Suitable chlorinated hydrocarbons may include dichloromethane, carbon tetrachloride or chloroform.
  • Suitable ethers may include diethyl ether, ethyl methyl ether, di-isopropyl ether, tetrahydrofuran or 1, 4-dioxane.
  • Suitable amides may include N, N- dimethylformamide or N, N-dimethylacetamide.
  • Suitable sulphoxides may include dimethyl sulfoxide or diethyl sulphoxide.
  • Suitable alkyl acetates may include ethyl acetate or di-isopropyl acetate.
  • the solvent may be selected from the group of ketones and alcohols.
  • Febuxostat may be contacted with the co-crystal former at ambient temperature to the reflux temperature of the solvent.
  • febuxostat may be contacted with the co-crystal former in a solvent at ambient temperature. In another embodiment, febuxostat may be contacted with the co-crystal former in a solvent at a temperature of about 45°C to about 60°C.
  • the reaction mixture formed by contacting febuxostat with the co-crystal former may optionally be kept in a freezer at a temperature of about -18°C to -20°C for about 5 minutes to about 1 hour to cause crystallization.
  • the reaction mixture formed by contacting febuxostat with the co-crystal former may also be stirred at ambient temperature for about 5 days to about 20 days.
  • Febuxostat co-crystals may be further purified by carrying out one or more crystallizations from a solvent.
  • the solvent may be selected from the group comprising of alcohols, ketones, water, carboxylic acids, chlorinated hydrocarbons, amides, sulphoxides, ethers, or mixtures thereof. Suitable alcohols, ketones, carboxylic acids, chlorinated hydrocarbons, amides, sulphoxides and ethers may include those described above for preparing febuxostat co-crystals.
  • the solution may be kept in a freezer at a temperature of about -18°C to -20°C for about 5 minutes to about 1 hour to accomplish crystallization.
  • Isolation may be accomplished by concentration, precipitation, cooling, filtration or centrifugation followed by drying. Any suitable method of drying may be employed, such as air drying, drying under reduced pressure, vacuum tray drying, or a combination thereof.
  • the co-crystals of febuxostat may be dried for a period of about 2 hours to about 25 days.
  • Febuxostat co-crystals of the present invention may be used to prepare new solid drug forms of febuxostat. Thus, improving the physicochemical properties of febuxostat. Further advantages of the co-crystals of the present invention include ease of preparation and formulation, improved bioavailability and efficacy, better solubility, and improved stability. Febuxostat co-crystals of the present invention may provide new routes of administration and reduced side-effects.
  • Table 4 provides thermal stability for febuxostat-urea co-crystals, febuxostat- nicotinamide co-crystals and febuxostat-caffeine co-crystals.
  • Table 5 provides solubility data for febuxostat Form A, febuxostat-urea co- crystals, febuxostat-nicotinamide co-crystals and febuxostat-caffeine co-crystals.
  • the solubility of febuxostat-nicotinamide and febuxostat-caffeine co-crystals are significantly better than Form A, which is the marketed form of febuxostat.
  • Table 5 Solubility Data of Febuxostat Form A and Febuxostat Co-crystals
  • Febuxostat co-crystal(s) of the present invention may be administered as part of a pharmaceutical composition for the chronic management of hyperuricemia in patients with gout.
  • pharmaceutical composition(s) which include febuxostat co-crystal(s) of the present invention, and one or more pharmaceutically acceptable carriers, diluents or excipients and optionally other therapeutic ingredients.
  • the febuxostat co-crystal(s) of the present invention may conventionally be formulated into tablets, capsules, suspensions, dispersions, injectables and other pharmaceutical forms. Any suitable route of administration may be employed, for example peroral or parental.
  • X-ray diffraction patterns were recorded using Panalytical Expert PRO with Xcelerator as detector, 3-40 as scan range, 0.02 as step size and 3-40° 2 ⁇ as range.
  • febuxostat-urea co-crystals 1.75 g of febuxostat-urea co-crystals were dissolved in acetone (17.5 mL) at about 55°C. The solution was kept in freezer at about -18°C to -20°C for about 20 minutes. The contents were filtered and air dried at ambient temperature for about 5 hours to obtain febuxostat-urea co-crystals.
  • febuxostat-nicotinamide co-crystals 1.75 g of febuxostat-nicotinamide co-crystals were dissolved in acetone (17.5 mL) at about 55°C. The solution was kept in freezer at about -18°C to -20°C for about 15 minutes. The contents were filtered and air dried at ambient temperature for about 5 hours to obtain febuxostat-nicotinamide co-crystals.
  • Febuxostat-caffeine co-crystals (1.500 g) were dissolved in acetone (25 mL) at about 55°C. The solution was kept in a freezer at about -18°C to -20°C for about 15 minutes. The contents were filtered and air dried at ambient temperature for about 5 hours to obtain febuxostat-caffeine co-crystals. Yield: 55.64% b) Febuxostat (0.9800 g) and caffeine (1.2050 g) were dissolved in 2-propanol (250 mL) at about 65°C. The solution was kept aside at ambient temperature for about 18 days for slow solvent evaporation. Co-crystals formation was observed.
  • Febuxostat-caffeine co-crystals (1.500 g) were dissolved in acetone (25 mL) at about 55°C. The solution was kept in a freezer at about -18°C to -20°C for about 15 minutes to accomplish crystallization. The contents were filtered and air dried at ambient temperature for about 5 hours to obtain febuxostat-caffeine co-crystals (0.8565 g).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des co-cristaux de fébuxostat, des procédés pour leur préparation et leur utilisation pour le contrôle chronique de l'hyperuricémie chez des patients atteints de goutte.
PCT/IB2012/050230 2011-01-21 2012-01-17 Co-cristaux de fébuxostat WO2012098501A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN152DE2011 2011-01-21
IN152/DEL/2011 2011-01-21

Publications (1)

Publication Number Publication Date
WO2012098501A1 true WO2012098501A1 (fr) 2012-07-26

Family

ID=45688919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/050230 WO2012098501A1 (fr) 2011-01-21 2012-01-17 Co-cristaux de fébuxostat

Country Status (1)

Country Link
WO (1) WO2012098501A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104177308A (zh) * 2014-07-31 2014-12-03 浙江中医药大学 三种新型非布司他药物共晶及其制备方法
KR20170002104A (ko) 2015-06-29 2017-01-06 순천향대학교 산학협력단 페북소스타트의 공결정 및 그의 제조방법
CN106565627A (zh) * 2016-10-10 2017-04-19 扬子江药业集团有限公司 一种非布司他药用晶型的制备方法
CN108530382A (zh) * 2018-03-20 2018-09-14 华南理工大学 一种非布索坦川芎嗪共晶体及其制备方法和用途
EP3001814B1 (fr) * 2013-03-15 2021-05-19 Allen, Davidoff Formulations d'inhibiteur de xanthine oxydase

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614520A (en) 1990-11-30 1997-03-25 Teijin Limited 2-arylthiazole derivatives and pharmaceutical composition thereof
WO2004078163A2 (fr) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
EP2039691A1 (fr) * 2006-06-23 2009-03-25 Teijin Pharma Limited Procédé de fabrication d'un polymorphe d'acide 2-(3-cyano-4- isobutyloxyphenyl)-4- methyl-5-thiazolecarboxylique
US7541475B2 (en) 2003-07-30 2009-06-02 Abbott Laboratories Substituted thiazoles
US20100317702A1 (en) * 2009-06-10 2010-12-16 Teva Pharmaceutical Industries Ltd. Crystalline form of febuxostat

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614520A (en) 1990-11-30 1997-03-25 Teijin Limited 2-arylthiazole derivatives and pharmaceutical composition thereof
WO2004078163A2 (fr) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
US7541475B2 (en) 2003-07-30 2009-06-02 Abbott Laboratories Substituted thiazoles
EP2039691A1 (fr) * 2006-06-23 2009-03-25 Teijin Pharma Limited Procédé de fabrication d'un polymorphe d'acide 2-(3-cyano-4- isobutyloxyphenyl)-4- methyl-5-thiazolecarboxylique
US20090203919A1 (en) 2006-06-23 2009-08-13 Mitsutaka Kitamura Method for producing crystal polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid
US20100317702A1 (en) * 2009-06-10 2010-12-16 Teva Pharmaceutical Industries Ltd. Crystalline form of febuxostat

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALMARSSON ET AL: "Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals reprepsent a new path to improved medicines", CHEMICAL COMMUNICATIONS - CHEMCOM; [6015D], ROYAL SOCIETY OF CHEMISTRY, GB, 1 January 2004 (2004-01-01), pages 1889 - 1896, XP002415977, ISSN: 1359-7345, DOI: 10.1039/B402150A *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3001814B1 (fr) * 2013-03-15 2021-05-19 Allen, Davidoff Formulations d'inhibiteur de xanthine oxydase
US11406713B2 (en) 2013-03-15 2022-08-09 Xortx Therapeutics, Inc. Xanthine oxidase inhibitor formulations
CN104177308A (zh) * 2014-07-31 2014-12-03 浙江中医药大学 三种新型非布司他药物共晶及其制备方法
KR20170002104A (ko) 2015-06-29 2017-01-06 순천향대학교 산학협력단 페북소스타트의 공결정 및 그의 제조방법
KR101821855B1 (ko) * 2015-06-29 2018-01-24 순천향대학교 산학협력단 페북소스타트의 공결정 및 그의 제조방법
CN106565627A (zh) * 2016-10-10 2017-04-19 扬子江药业集团有限公司 一种非布司他药用晶型的制备方法
CN108530382A (zh) * 2018-03-20 2018-09-14 华南理工大学 一种非布索坦川芎嗪共晶体及其制备方法和用途

Similar Documents

Publication Publication Date Title
KR101019451B1 (ko) 이마티닙 메실레이트의 다형 및 신규한 결정형과 비결정형및 α형의 제조 방법
US8217061B2 (en) Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
US7491726B2 (en) Crystalline forms of aripiprazole
EP2712865B1 (fr) Procédé amélioré pour la préparation d'ambrisentan
WO2012027543A1 (fr) Formes solides de dabigatran étexilate et de dabigatran étexilate mésylate et leurs méthodes de préparation
US20040010151A1 (en) Lansoprazole polymorphs and processes for preparation thereof
US11332467B2 (en) Solid state forms of palbociclib dimesylate
US20100234599A1 (en) Method for preparing acid addition salts of polyacidic basic compounds
US9676741B1 (en) Co-crystal of dapagliflozin with citric acid
US20090076272A1 (en) Polymorphs of eszopiclone malate
WO2012098501A1 (fr) Co-cristaux de fébuxostat
KR101710740B1 (ko) 2-［［［2-［(히드록시아세틸)아미노］-4-피리디닐］메틸］티오］-ｎ-［4-(트리플루오로메톡시)페닐］-3-피리딘카르복사미드의 벤젠술폰산염, 이의 결정, 이의 결정 다형 및 이들의 제조 방법
WO2017106641A1 (fr) Formes à l'état solide de brexpiprazole
AU2017303898A1 (en) Production method for pyrazole-amide compound
TW201829420A (zh) [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式
WO2011080651A2 (fr) Formes polymorphes de fébuxostat
US20220002302A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
US20090012296A1 (en) Processes for the preparation of crystalline form beta of imatinib mesylate
WO2018185664A1 (fr) Solvates d'éluxadoline
US7473780B2 (en) Drying process for preparing crystalline solid famciclovir
JP2006513250A (ja) アラニン系化合物、その製造方法及び用途
CN106957311B (zh) 雷替曲塞的溶剂化物及其制备方法
WO2023187762A1 (fr) Co-cristaux de bromhydrate de vortioxétine
CN115417825A (zh) 一种五元或六元稠环并嘧啶类环丙基萘衍生物及其制备方法与应用
EP3170817A1 (fr) Co-cristaux de composés de benzimidazole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12704910

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12704910

Country of ref document: EP

Kind code of ref document: A1